Biotech Values

[DewDiligence]

ARWR, Takeda ink deal for commercialization of ARO-AAT:

https://www.businesswire.com/news/home/20201008005340/en/

• Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M

• Investigational medicine ARO-AAT to be co-developed and co-commercialized in the United States by Takeda and Arrowhead under a 50/50 profit-sharing structure

• Takeda receives exclusive license to commercialize ARO-AAT outside the U.S.